rosuvastatin and SARS-Cov-2
Phase 3
- Registration Number
- IRCT20230722058883N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
patients who were not currently taking statin treatment
patients who had a confirmed diagnosis of COVID-19 based on imaging or PCR results.
Exclusion Criteria
patients with known liver disease, cirrhosis, autoimmune hepatitis, chronic viral hepatitis, rhabdomyolysis myopathy, severe kidney disease, a history of statin sensitivity, and higher-than-normal ALT and CPK in the initial test.
Patients who had previously taken statins at different dosages as well as women who were pregnant or nursing
If the patient developed symptoms of hepatitis or myopathy, muscle weakness and increased liver and muscle enzymes after taking statin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of disease was evaluated based on the following variables: the temperature measured by thermometer and arterial oxygen saturation measured by pulse oximeter; observation of vital signs including heart and respiratory rate on the first day of hospitalization and the day of discharge; CBC-related information including the level of CRP, ESR, WBC, Plt, ALT and CPK at the beginning of hospitalization and on the day of discharge; length of hospitalization as well as the need for ICU and intubation; shortness of breath assessed based on the Borg questionnaire and cough based on the LCQ questionnaire on the first day and at the time of discharge and after two weeks of statin administration (evaluated by phone call); and lastly, one-month mortality in cases and controls. Timepoint: on the first day and at the time of discharge and after two weeks and 1 month of statin administration. Method of measurement: thermometer, pulse oximeter, CBC, Borg questionnaire and LCQ questionnaire.
- Secondary Outcome Measures
Name Time Method